Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이대호 | - |
dc.date.available | 2020-12-23T00:40:14Z | - |
dc.date.created | 2020-07-02 | - |
dc.date.issued | 2020-06 | - |
dc.identifier.issn | 2093-596X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/79392 | - |
dc.description.abstract | Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver diseases and can progress to advanced fibrosis and end-stageliver disease. Thus, intensive research has been performed to develop noninvasive methods for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Currently, no single noninvasive tool covers all of the stages of pathologies and conditions ofNAFLD, and the cost and feasibility of known techniques are also important issues. Blood biomarkers for NAFLD may be useful toselect subjects who need ultrasonography (US) screening for NAFLD, and noninvasive tools for assessing fibrosis may be helpful toexclude the probability of significant fibrosis and to predict advanced fibrosis, thus guiding the decision of whether to perform liverbiopsy in patients with NAFLD. Among various methods, magnetic resonance-based methods have been shown to perform betterthan other methods in assessing steatosis as well as in detecting hepatic fibrosis. Many genetic markers are associated with the development and progression of NAFLD. Further well-designed studies are needed to determine which biomarker panels, imaging studies, genetic marker panels, or combinations thereof perform well for diagnosing NAFLD, differentiating NASH and fibrosis, andfollowing-up NAFLD, respectively. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한내분비학회 | - |
dc.relation.isPartOf | Endocrinology and Metabolism | - |
dc.title | Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease | - |
dc.title.alternative | Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000596724000006 | - |
dc.identifier.doi | 10.3803/EnM.2020.35.2.243 | - |
dc.identifier.bibliographicCitation | Endocrinology and Metabolism, v.35, no.2, pp.243 - 259 | - |
dc.identifier.kciid | ART002602436 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85089384169 | - |
dc.citation.endPage | 259 | - |
dc.citation.startPage | 243 | - |
dc.citation.title | Endocrinology and Metabolism | - |
dc.citation.volume | 35 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | 이대호 | - |
dc.subject.keywordAuthor | Evaluation | - |
dc.subject.keywordAuthor | Non-alcoholic fatty liver disease | - |
dc.subject.keywordAuthor | Liver steatosis | - |
dc.subject.keywordAuthor | Fibrosis | - |
dc.subject.keywordAuthor | Biomarkers | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.